STING1 and neuroendocrine neoplasm: Particularly low rates of STING positivity were observed for prostatic adenocarcinomas (up to 11%), different subtypes of renal cell carcinomas (RCC; 18.8–24.5%), neuroendocrine tumors (NETs) of various sites (17.0–28.6%), neuroendocrine carcinomas (NECs; 12.5–38.5%), and Merkel cell carcinoma of the skin (5%) and small cell neuroendocrine carcinomas of the bladder (31.6%) and the prostate (17.6%).